Skip to content
by Legal Desire
31 August 2024

Latham & Watkins Advises Arcus Biosciences in US$250 Million Growth Facility

Advising firms

Deal team

13 lawyers named
LawyerFirmSeniorityPracticeOffice
Haim Zaltzman Lead Latham & Watkins LLP Partner transactional Not stated
Mark Roeder Lead Latham & Watkins LLP Partner transactional Not stated
Trevor Church Latham & Watkins LLP Associate Not stated Not stated
Erin Cusenbary Latham & Watkins LLP Associate Not stated Not stated
Tyler Davis Latham & Watkins LLP Associate Not stated Not stated
John Williams Latham & Watkins LLP Partner corporate Not stated
Jekkie Kim Latham & Watkins LLP Partner intellectual property Not stated
Mizuna Sekine Latham & Watkins LLP Associate intellectual property Not stated
Eric Cho Latham & Watkins LLP Partner tax Not stated
Betty Pang Latham & Watkins LLP Partner healthcare Not stated
Chad Jennings Latham & Watkins LLP Counsel FDA/regulatory Not stated
Reza Mojtabaee-Zamani Latham & Watkins LLP Partner transaction Not stated
Kevin Zhang Latham & Watkins LLP Associate transaction Not stated

Stated terms

Stated value
USD 250m (US$250 million)
What the figure measures
Facility amount
Client
Arcus Biosciences, Inc.Borrower
Counterparties
Hercules Capital, Inc. (Lenders)